Association Between State-Wide Cardiac Quality Improvement Program and Costs Following Intervention for Coronary Artery Disease

IF 2.4 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Clinical Cardiology Pub Date : 2024-11-18 DOI:10.1002/clc.70030
Edwin S. Wong, Joshua Nelson, Richard Whitten, Charles Maynard, Jeannie Collins-Brandon, Kristin Sitcov, Ravi S. Hira
{"title":"Association Between State-Wide Cardiac Quality Improvement Program and Costs Following Intervention for Coronary Artery Disease","authors":"Edwin S. Wong,&nbsp;Joshua Nelson,&nbsp;Richard Whitten,&nbsp;Charles Maynard,&nbsp;Jeannie Collins-Brandon,&nbsp;Kristin Sitcov,&nbsp;Ravi S. Hira","doi":"10.1002/clc.70030","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Since 2010, all non-VA hospitals performing cardiac surgeries and percutaneous interventions in Washington State have participated in the Cardiac Care Outcomes Assessment Program (COAP), a data-driven, physician-led collaborative quality improvement (QI) collaborative. Prior literature has demonstrated QI programs such as COAP can avert avoidable utilization such as hospital readmissions. However, it is unknown whether such improvements translate into economic benefits.</p>\n </section>\n \n <section>\n \n <h3> Hypothesis</h3>\n \n <p>This study compared downstream healthcare costs between patients undergoing cardiac interventions for coronary artery disease (CAD) at hospitals that were and were not participating in COAP.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>Post hoc analysis of Medicare administrative and claims data examined 2.5 million randomly selected deidentified beneficiaries receiving a percutaneous coronary intervention or coronary artery bypass grafting between 2013 and 2020. Total costs were defined as all reimbursements paid by Medicare for up to 5 years following cardiac intervention. Because all non-VA hospitals in Washington State participated in COAP, we compared respective groups of patients receiving intervention in Washington State with all non-Washington states, adjusting for patient demographics and comorbidity. To model costs, we applied a multipart estimator, which distinguishes the impact of QI program participation due to survival and utilization while accounting for censoring.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Total 5-year downstream costs were $3861 lower (95% confidence interval [CI] = $1794 to $5741) among patients receiving cardiac intervention at COAP-exposed hospitals. Lower costs were largely driven by lower utilization during calendar quarters where death was not observed.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>Participation in this state-wide cardiac quality improvement program was associated with economic benefits in patients receiving intervention for CAD.</p>\n </section>\n </div>","PeriodicalId":10201,"journal":{"name":"Clinical Cardiology","volume":"47 11","pages":""},"PeriodicalIF":2.4000,"publicationDate":"2024-11-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/clc.70030","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Cardiology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/clc.70030","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Since 2010, all non-VA hospitals performing cardiac surgeries and percutaneous interventions in Washington State have participated in the Cardiac Care Outcomes Assessment Program (COAP), a data-driven, physician-led collaborative quality improvement (QI) collaborative. Prior literature has demonstrated QI programs such as COAP can avert avoidable utilization such as hospital readmissions. However, it is unknown whether such improvements translate into economic benefits.

Hypothesis

This study compared downstream healthcare costs between patients undergoing cardiac interventions for coronary artery disease (CAD) at hospitals that were and were not participating in COAP.

Methods

Post hoc analysis of Medicare administrative and claims data examined 2.5 million randomly selected deidentified beneficiaries receiving a percutaneous coronary intervention or coronary artery bypass grafting between 2013 and 2020. Total costs were defined as all reimbursements paid by Medicare for up to 5 years following cardiac intervention. Because all non-VA hospitals in Washington State participated in COAP, we compared respective groups of patients receiving intervention in Washington State with all non-Washington states, adjusting for patient demographics and comorbidity. To model costs, we applied a multipart estimator, which distinguishes the impact of QI program participation due to survival and utilization while accounting for censoring.

Results

Total 5-year downstream costs were $3861 lower (95% confidence interval [CI] = $1794 to $5741) among patients receiving cardiac intervention at COAP-exposed hospitals. Lower costs were largely driven by lower utilization during calendar quarters where death was not observed.

Conclusions

Participation in this state-wide cardiac quality improvement program was associated with economic benefits in patients receiving intervention for CAD.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
全州心脏质量改进计划与冠状动脉疾病干预后的成本之间的关系。
背景:自 2010 年以来,华盛顿州所有进行心脏手术和经皮介入治疗的非退伍军人医院都参加了心脏护理结果评估计划 (COAP),这是一项由医生主导的数据驱动型协作质量改进 (QI) 计划。先前的文献表明,COAP 等 QI 计划可以避免可避免的使用,如再次入院。然而,这种改善是否能转化为经济效益尚不得而知:本研究比较了在参与和未参与 COAP 的医院接受冠状动脉疾病(CAD)心脏介入治疗的患者的下游医疗成本:方法:对医疗保险管理和报销数据进行事后分析,对 2013 年至 2020 年间接受经皮冠状动脉介入治疗或冠状动脉旁路移植术的 250 万名随机抽取的身份不明受益人进行了调查。总费用定义为心脏介入治疗后 5 年内医疗保险支付的所有报销费用。由于华盛顿州的所有非退伍军人医院都参与了 COAP,因此我们将华盛顿州接受介入治疗的患者组别与所有非华盛顿州的患者组别进行了比较,并对患者的人口统计学特征和合并症进行了调整。为了建立成本模型,我们采用了多部分估算器,该估算器可区分参与质量改进项目对生存和使用的影响,同时考虑到删减因素:结果:在COAP暴露医院接受心脏介入治疗的患者5年下游总费用降低了3861美元(95%置信区间[CI] = 1794美元至5741美元)。成本降低的主要原因是在未观察到死亡的日历季度内使用率较低:结论:参与这项全州范围的心脏质量改进计划可为接受 CAD 干预治疗的患者带来经济效益。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Clinical Cardiology
Clinical Cardiology 医学-心血管系统
CiteScore
5.10
自引率
3.70%
发文量
189
审稿时长
4-8 weeks
期刊介绍: Clinical Cardiology provides a fully Gold Open Access forum for the publication of original clinical research, as well as brief reviews of diagnostic and therapeutic issues in cardiovascular medicine and cardiovascular surgery. The journal includes Clinical Investigations, Reviews, free standing editorials and commentaries, and bonus online-only content. The journal also publishes supplements, Expert Panel Discussions, sponsored clinical Reviews, Trial Designs, and Quality and Outcomes.
期刊最新文献
Heart Failure Is Closely Associated With the Expression Characteristics of Type I Interferon-Related Genes. Digital Devices for Arrhythmia Detection: What Is Still Missing? "Letter to the Editor: A Correction to [Outcomes of Bolus Dose Furosemide Versus Continuous Infusion in Patients With Acute Decompensated Left Ventricular Failure and Atrial Fibrillation]". Predictive Value of Machine Learning for the Risk of In-Hospital Death in Patients With Heart Failure: A Systematic Review and Meta-Analysis. Unmasking the Hidden Threat: The Role of Left Ventricular Subendocardial Involvement in Autoimmune Rheumatic Disease.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1